CD315抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD315 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using CD315 mouse mAb with DAB staining.    

  
  

CD315. also known as TIM-3 (T cell immunoglobulin and mucin domain-containing protein 3), is an immune checkpoint molecule first identified in 2002. It is a type I transmembrane protein expressed on immune cells, including T cells, natural killer (NK) cells, and dendritic cells. Structurally, it contains an immunoglobulin variable domain, a mucin-like domain, and a cytoplasmic tail with tyrosine phosphorylation sites. TIM-3 plays a dual role in immune regulation: it modulates T cell exhaustion in chronic infections and cancer while also contributing to immune tolerance and homeostasis.

In cancer, TIM-3 is often co-expressed with PD-1 on dysfunctional "exhausted" T cells, making it a key target for immunotherapy. Antibodies targeting CD315 aim to block its interaction with ligands like galectin-9. phosphatidylserine, or CEACAM-1. thereby reversing T cell suppression and restoring anti-tumor immunity. Preclinical studies show that anti-CD315 antibodies enhance T cell activation and synergize with anti-PD-1 therapies.

Several anti-TIM-3 antibodies (e.g., cobolimab, MBG453/sabatolimab) are in clinical trials for solid tumors and hematologic malignancies. Challenges include optimizing dosing, managing immune-related adverse events, and identifying predictive biomarkers. Research continues to explore its role in autoimmune diseases, viral infections, and combination therapies. As a next-gen checkpoint inhibitor, CD315 antibodies hold promise for overcoming resistance to existing immunotherapies.